Haoxi Health (NASDAQ: HAO) and Eaglepoint AI (subsidiary of GMM) signed a three-year strategic cooperation to develop an AI health management platform in China. The partnership will combine Haoxi's marketing networks and user reach with Eaglepoint's Aquila data engine for R&D, model training, and a SaaS release called "AI Digital Health Manager" targeting sub-healthy and chronic disease populations.
The collaboration covers intelligent nutrition, chronic disease risk assessment, and digital therapeutics, with Eaglepoint handling model iteration and data-security compliance.
Loading...
Loading translation...
Positive
Three-year strategic agreement to develop AI health management platform
Launch of AI Digital Health Manager SaaS targeting sub-healthy and chronic disease users
Haoxi's marketing reach backed by "tens of billions" of online advertising data points
Negative
No financial terms or revenue projections disclosed for the three-year cooperation
No concrete commercial timelines beyond an initial "first phase" launch
News Market Reaction – HAO
-13.62%1.7x vol
6 alerts
-13.62%Session close to close
+2.1%Peak Tracked
-21.8%Trough Tracked
$76.39MMarket Cap
1.7xRel. Volume
In the Mar 3 session, HAO declined 13.62%, reflecting a significant negative market reaction.
Argus tracked a peak move of +2.1% during that session.
Argus tracked a trough of -21.8% from its starting point during tracking.
Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.
The stock dropped -13.6% in the session following this news. A negative reaction despite AI-focused ...
Analysis
The stock dropped -13.6% in the session following this news. A negative reaction despite AI-focused partnership news would contrast with the prior AI collaboration in September 2024, which saw a +11.27% move. Investors may be weighing financing history and dilution risk from recent capital-raising frameworks against the strategic upside of expanding into AI health management. If the market questioned commercialization timelines or profitability, the stock’s response could diverge from earlier enthusiasm around similar announcements.
Key Figures
Strategic cooperation term:3 yearsModel iteration gain:3.5 timesATM program size:$80,000,000+5 more
8 metrics
Strategic cooperation term3 yearsLength of Haoxi–Eaglepoint AI strategic agreement
Model iteration gain3.5 timesEfficiency improvement from Eaglepoint’s Aquila platform vs mainstream models
ATM program size$80,000,000Class A share at-the-market program established January 23, 2026
ATM commission2.5%Sales agent commission on ATM gross proceeds
Reference price$1.56Class A reference price used in January 23, 2026 prospectus
FY2025 revenue$32.80 millionRevenue year ended June 30, 2025
FY2025 net income$3,876,680Net income year ended June 30, 2025
IPO gross proceeds$11,040,000IPO proceeds at $4.00 per share, including over-allotment
Announced AI marketing partnership integrating Gausspeed with Haoxi’s applications.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Prior AI partnership news in 2024 also saw a positive price reaction, suggesting investors have historically rewarded AI-related collaborations.
Recent Company History
In September 2024, Haoxi Health announced a strategic AI marketing partnership with a Global Mofy AI subsidiary, integrating the Gausspeed generative AI platform to enhance data analysis, creative automation, and decision-making. The stock moved +11.27% over 24 hours. The current agreement with another Global Mofy AI subsidiary, Eaglepoint AI, again focuses on AI-driven capabilities, this time for health management in China, extending the company’s AI collaboration theme from marketing into healthcare applications.
Key Terms
multimodal model evaluation system, AI health management platform, AI-enabled preventive healthcare, digital therapeutics, +4 more
8 terms
multimodal model evaluation systemtechnical
"deployed its Aquila data engine and multimodal model evaluation system in a high-growth"
A multimodal model evaluation system is a set of tests and metrics that checks how well an artificial intelligence system understands and uses different kinds of input—such as text, images, charts, or audio—together. For investors this matters because it measures reliability, accuracy, and safety of AI-driven products and services; like a car inspection that tests brakes, lights and engine together, it helps predict whether an AI-powered offering will perform, meet regulations, and avoid costly errors or reputation damage.
AI health management platformtechnical
"resources to launch an AI health management platform in China."
A AI health management platform is software that uses artificial intelligence to collect and analyze health data, coordinate care tasks, and deliver personalized recommendations to patients and providers. Think of it as a smart assistant or air-traffic controller for medical information that aims to improve outcomes, reduce wasted costs, and scale services across many users. Investors care because these platforms can generate recurring revenue, lower healthcare expenses, and face adoption, regulatory and data-privacy risks that affect growth and valuation.
AI-enabled preventive healthcaremedical
"explore collaboration in the AI-enabled preventive healthcare applications, including"
AI-enabled preventive healthcare uses computer learning to analyze medical records, wearable data, genetics and lifestyle information to spot health risks early and suggest actions to avoid illness — like a weather forecast that warns you to carry an umbrella before a storm. It matters to investors because it can lower long-term care costs, create recurring-revenue products (subscriptions, monitoring services), and expand market reach, while also carrying regulatory, privacy and accuracy risks that can affect adoption and returns.
digital therapeuticsmedical
"preventive healthcare applications, including intelligent nutrition, chronic disease risk assessment, and digital therapeutics."
Digital therapeutics are clinically proven software programs or apps designed to prevent, manage or treat medical conditions, often used alongside or instead of drugs and devices. They matter to investors because they can scale like software, require regulatory approval and payment from insurers or health systems, and thus offer potential recurring revenue, lower delivery costs and new market opportunities in healthcare — like a virtual prescription that replaces or enhances traditional treatment.
model trainingtechnical
"Eaglepoint AI will be responsible for technical support in model training, data security"
The process of teaching a computer system to recognize patterns and make predictions by feeding it lots of example data and adjusting its internal settings until its answers improve. Investors care because how well a model is trained affects a product’s accuracy, reliability, speed to market, and operating costs, and it can influence competitive advantage, regulatory risk, and potential for biased or unsafe outcomes—like training an employee to perform a critical job correctly.
data security compliancetechnical
"technical support in model training, data security compliance, and algorithm iteration."
Data security compliance is the set of laws, industry rules and internal practices a company follows to protect customer and business information from theft, loss or misuse. Like a building’s fire code, meeting these standards reduces the chance of costly data breaches, regulatory fines and reputational damage that can hurt revenue and stock value, so investors view strong compliance as a sign of lower operational and legal risk.
algorithm iterationtechnical
"data security compliance, and algorithm iteration."
Algorithm iteration is one cycle of changing and re-running a computer routine or set of rules to improve how it performs — for example adjusting logic, inputs or settings and testing the outcome. For investors, iterations matter because they drive faster improvements, fewer mistakes and more reliable signals from trading systems, risk models or analysis tools; like tweaking a recipe and tasting each time, better iterations can increase returns or reduce losses and competitive risk.
SaaS systemtechnical
"project will launch the "AI Digital Health Manager" SaaS system targeting sub-healthy"
A SaaS system is software hosted and maintained by a provider and delivered to customers over the internet, where users access the application through a web browser instead of installing it on their own computers—like renting a household appliance that the supplier cleans and repairs for you. For investors it matters because the business model usually generates recurring subscription income and scales with added customers, making metrics such as recurring revenue, customer retention and customer turnover key indicators of future cash flow and profitability.
BEIJING, March 03, 2026 (GLOBE NEWSWIRE) -- HAOXI HEALTH TECHNOLOGY LIMITED (NASDAQ: HAO) (the “Haoxi Health”), a U.S. publicly listed company, and Eaglepoint AI Inc., a subsidiary of Global Mofy AI Limited (NASDAQ: GMM), today jointly announced the signing of a three-year strategic cooperation agreement. The two parties will jointly commit R&D, data, and channel resources to launch an AI health management platform in China. Haoxi Health believes that this partnership marks its's exploration of potential opportunities in the AI-enabled healthcare sector. This collaboration also represents the first time that Eaglepoint AI has deployed its Aquila data engine and multimodal model evaluation system in a high-growth health management scenario.
Under the agreement, both parties will explore collaboration in the AI-enabled preventive healthcare applications, including intelligent nutrition, chronic disease risk assessment, and digital therapeutics. HAOXI HEALTH plans to contribute its marketing networks to provide user reach and commercial conversion support, while Eaglepoint AI will be responsible for technical support in model training, data security compliance, and algorithm iteration. The first phase of the project will launch the "AI Digital Health Manager" SaaS system targeting sub-healthy and chronic disease populations.
Mr. Fan Zhen, CEO of Haoxi Health, stated: "The company has long served domestic and international healthcare clients, managing tens of billions of online advertising data points. We understand clients' urgent demand for personalized, quantifiable health management solutions. Eaglepoint AI possesses capabilities in data governance and multimodal model evaluation. Its proprietary Aquila platform has achieved automated comparative experiments with mainstream large models including Claude, GPT, and Gemini, improving model iteration efficiency by 3.5 times. We believe this collaboration will integrate HAOXI's marketing traffic advantages with Eaglepoint's algorithmic strengths."
Both parties believe that the collaboration between HAOXI HEALTH and Eaglepoint AI will not only enhance digital marketing ROI for domestic healthcare enterprises but also provide health data pipelines for AI models, contributing to the competitive and cooperative landscape across the "Data + Algorithm + Traffic" dimensions.
About Haoxi Health Technology Limited
Haoxi Health Technology Limited is a Beijing-headquartered online marketing solution provider in China, specializing in serving healthcare industry advertiser clients. The Company's growth is driven by the rise of news feed ads and the rapid development of the healthcare sector. The Company offers one-stop online marketing solutions, especially in online short video marketing, helping advertisers acquire and retain customers on popular platforms in China, such as Toutiao, Douyin, WeChat, and Sina Weibo. It is dedicated to reducing costs, increasing efficiency, and providing easy online marketing solutions to advertisers.
Forward-Looking Statement
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions, and other factors discussed in the "Risk Factors" section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For more information, please contact:
Investor Relations
ir@haoximedia.com
FAQ
What did Haoxi Health (HAO) announce on March 3, 2026 about AI healthcare?
They announced a three-year strategic cooperation with Eaglepoint AI to build an AI health management platform in China. According to the company, the deal pairs Haoxi's marketing reach with Eaglepoint's Aquila engine for R&D and SaaS deployment.
What is the "AI Digital Health Manager" SaaS that HAO plans to launch?
It is a SaaS system targeting sub-healthy and chronic disease populations for preventive care and management. According to the company, the first phase will focus on intelligent nutrition, risk assessment, and digital therapeutics.
How will Eaglepoint AI contribute technically to the HAO partnership?
Eaglepoint will provide model training, algorithm iteration, and data-security compliance support. According to the company, its Aquila engine has automated comparative experiments and improved model iteration efficiency by 3.5 times.
What role will Haoxi Health (HAO) play in the partnership with Eaglepoint AI?
Haoxi will supply marketing networks, user reach, and commercial conversion support to scale uptake. According to the company, it leverages "tens of billions" of online advertising data points to drive user acquisition.
Does the March 3, 2026 announcement disclose financial terms or revenue impact for HAO?
No, the announcement does not disclose any financial terms, pricing, or projected revenue impact for the cooperation. According to the company, operational and technical responsibilities are described but monetary details were not provided.
What healthcare applications will the HAO and Eaglepoint collaboration explore?
They will explore AI-enabled preventive healthcare: intelligent nutrition, chronic disease risk assessment, and digital therapeutics. According to the company, these areas are the primary focus for the joint platform and initial SaaS offering.
